155 related articles for article (PubMed ID: 25445911)
1. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
[TBL] [Abstract][Full Text] [Related]
2. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
3. NKT TCR recognition of CD1d-α-C-galactosylceramide.
Patel O; Cameron G; Pellicci DG; Liu Z; Byun HS; Beddoe T; McCluskey J; Franck RW; Castaño AR; Harrak Y; Llebaria A; Bittman R; Porcelli SA; Godfrey DI; Rossjohn J
J Immunol; 2011 Nov; 187(9):4705-13. PubMed ID: 21964029
[TBL] [Abstract][Full Text] [Related]
4. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
5. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
6. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor alpha chain.
Yasuda N; Masuda K; Tsukui T; Teng A; Ishii Y
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):224-31. PubMed ID: 19748683
[TBL] [Abstract][Full Text] [Related]
7. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands.
Schiefner A; Fujio M; Wu D; Wong CH; Wilson IA
J Mol Biol; 2009 Nov; 394(1):71-82. PubMed ID: 19732779
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of bovine CD1d reveal altered αGalCer presentation and a restricted A' pocket unable to bind long-chain glycolipids.
Wang J; Guillaume J; Pauwels N; Van Calenbergh S; Van Rhijn I; Zajonc DM
PLoS One; 2012; 7(10):e47989. PubMed ID: 23110152
[TBL] [Abstract][Full Text] [Related]
9. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
10. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
11. Functional CD1d and/or NKT cell invariant chain transcript in horse, pig, African elephant and guinea pig, but not in ruminants.
Looringh van Beeck FA; Reinink P; Hermsen R; Zajonc DM; Laven MJ; Fun A; Troskie M; Schoemaker NJ; Morar D; Lenstra JA; Vervelde L; Rutten VP; van Eden W; Van Rhijn I
Mol Immunol; 2009 Apr; 46(7):1424-31. PubMed ID: 19185921
[TBL] [Abstract][Full Text] [Related]
12. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD1c enhances human invariant NKT cell activation by α-GalCer.
Fox LM; Miksanek J; May NA; Scharf L; Lockridge JL; Veerapen N; Besra GS; Adams EJ; Hudson AW; Gumperz JE
Cancer Immun; 2013; 13():9. PubMed ID: 23885215
[TBL] [Abstract][Full Text] [Related]
14. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice.
Freigang S; Zadorozhny V; McKinney MK; Krebs P; Herro R; Pawlak J; Kain L; Schrantz N; Masuda K; Liu Y; Savage PB; Bendelac A; Cravatt BF; Teyton L
J Clin Invest; 2010 Jun; 120(6):1873-84. PubMed ID: 20484813
[TBL] [Abstract][Full Text] [Related]
16. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
17. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
19. Human NKT cells express granulysin and exhibit antimycobacterial activity.
Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
[TBL] [Abstract][Full Text] [Related]
20. In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.
Fernandez CS; Jegaskanda S; Godfrey DI; Kent SJ
Clin Exp Immunol; 2013 Sep; 173(3):480-92. PubMed ID: 23656283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
